Yatsuga Chiho, Toyohisa Daiki, Fujisawa Takashi X, Nishitani Shota, Shinohara Kazuyuki, Matsuura Naomi, Ikeda Shinobu, Muramatsu Masaaki, Hamada Akinobu, Tomoda Akemi
Research Center for Child Mental Development, University of Fukui, Fukui, Japan.
Department of Child Development, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Brain Dev. 2014 Aug;36(7):620-5. doi: 10.1016/j.braindev.2013.08.006. Epub 2013 Sep 12.
This study ascertained the association between attention deficit/hyperactivity disorder (ADHD) in Japanese children and a polymorphism of catechol-O-methyltransferase (COMT), a dopamine-control gene. The secondary aim of the study was the evaluation of a putative association between methylphenidate (MPH) effect/adverse effects and the COMT genotype.
To ascertain the distribution of the Val158Met variant of COMT, 50 children meeting ADHD inclusion criteria were compared with 32 healthy children. Clinical improvement and the occurrence of adverse effects were measured before and 3 months after MPH administration in children with ADHD, and analyzed for genotype association. Wechsler Intelligence Scale for Children-Third Edition (WISC-III), age, MPH dose were included as co-variables.
The occurrence of the COMT Val/Val genotype was significantly higher in children with ADHD (χ(2)(1)=7.13, p<0.01). However, there was no significant difference in the Val/Val genotype according to disorder, and WISC and ADHD rating scale scores, after correcting for the interaction between disorder and COMT genotype. Furthermore, no significant difference in MPH effect/adverse effects was observed in association with the COMT genotype in the ADHD group.
These results showed a lack of association between the COMT Val/Val genotype and ADHD in Japan.
本研究确定了日本儿童注意力缺陷/多动障碍（ADHD）与多巴胺调控基因儿茶酚-O-甲基转移酶（COMT）多态性之间的关联。该研究的次要目的是评估哌甲酯（MPH）疗效/不良反应与COMT基因型之间的假定关联。
为确定COMT的Val158Met变异体的分布情况，将50名符合ADHD纳入标准的儿童与32名健康儿童进行比较。对ADHD儿童在服用MPH前及服用3个月后测量临床改善情况及不良反应的发生情况，并分析其与基因型的关联。将韦氏儿童智力量表第三版（WISC-III）、年龄、MPH剂量作为协变量纳入分析。
ADHD儿童中COMT Val/Val基因型的发生率显著更高（χ(2)(1)=7.13，p<0.01）。然而，在校正疾病与COMT基因型之间的相互作用后，根据疾病类型、WISC和ADHD评定量表评分，Val/Val基因型并无显著差异。此外，在ADHD组中，未观察到MPH疗效/不良反应与COMT基因型之间存在显著差异。
这些结果表明在日本，COMT Val/Val基因型与ADHD之间缺乏关联。
